[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fzrMnpak7ZIh86gDe1NTt9S7Svy_FCnWHrTfxd6PiXPc":8,"$f93CIO8FBvy4DA17CZMMpPsuvqsHBdb544ULTpBLKgrg":55,"$fTC0TroZmdGIl3UkfLQTsJqzIQFyPNqybJ53wWTh0KB4":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65195,862794,[],"https://cdn.yishi-tong.com/console/store-1/Si4P_fC5H_NUK1-yWqxbthvHo_drnUm_.jpg","周瀚","安丘市人民医院","普外科","主治医师",425,0,"乳腺癌早期治疗与颅脑转移：靶向治疗与耐药性用药指南","","https://ystcdn.venuertc.com/venue/AI/a1fad06e-aa39-4abd-bfc6-dd0e341c62cf.jpg","\u003Cdiv class=\"material-content\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌早期治疗与颅脑转移：靶向治疗与耐药性用药指南\u003C/h1>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、开篇导语\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      说起来，靶向药物已经逐渐成为乳腺癌治疗领域的重要成员，尤其是HER2靶向药物。许多朋友对它有听说，但在实际用药中，剂型、用法、合用药物、常见反应等细节却常被忽略。今天就来拆解这几类靶向药物的实用用药技巧和风险防范措施，共7大关键点，助你用药更放心、更安全。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light2\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. HER2靶向药物：分类、成分与剂型\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      HER2阳性乳腺癌常选用特定靶向药。主要代表有曲妥珠单抗（Trastuzumab）、帕妥珠单抗（Pertuzumab）、拉帕替尼（Lapatinib）、吡咯替尼（Pyrotinib）、T-DM1（Trastuzumab Emtansine）等。\n      \u003Cbr>\n      \u003Cspan class=\"material-emoji\">🔬\u003C/span> \n      \u003Cspan class=\"material-strong\">常见剂型：\u003C/span> 曲妥珠单抗与T-DM1多为注射剂，帕妥珠单抗为注射剂，拉帕替尼、吡咯替尼则多为口服片剂。不同剂型决定了用药步骤和注意事项的差异。比如，注射剂需要在医疗机构、由专业人员操作，并定期监测相关指标。\n      \u003Cbr>\n      \u003Cspan class=\"material-strong\">产品规格：\u003C/span> 以曲妥珠单抗为例，常见有150mg/瓶或420mg/瓶规格，帕妥珠单抗为420mg/瓶，拉帕替尼常见为250mg片剂（每盒60片装）。\n    \u003C/p>\n    \u003Cul class=\"material-ul\">\n      \u003Cli>曲妥珠单抗、T-DM1：静脉注射\u003C/li>\n      \u003Cli>帕妥珠单抗：静脉注射\u003C/li>\n      \u003Cli>拉帕替尼、吡咯替尼：口服片剂\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-tip\">正确做法：用药前清点剂型与规格，结合医生处方选择合适产品。\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light3\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. HER2靶向药物的作用机制与药代动力学\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">🧬\u003C/span>\n      HER2靶向药物通过阻断细胞表面HER2蛋白，阻止异常信号传递，最终抑制细胞增殖。\u003Cbr>\n      \u003Cspan class=\"material-strong\">简述两大机制：\u003C/span>\n      \u003C/p>\u003Cul class=\"material-ul\">\n        \u003Cli>单抗类（曲妥珠单抗、帕妥珠单抗）：直接结合HER2受体，阻断信号，促进免疫细胞清除异常细胞。\u003C/li>\n        \u003Cli>小分子类（拉帕替尼、吡咯替尼）：靶向HER2的酪氨酸激酶结构域，阻断下游信号通路。\u003C/li>\n      \u003C/ul>\n      由于分子大小不同，注射制剂多为单抗类，作用时间长，口服小分子多需每日服用，坚持规范才有良好效果。\n      \u003Cp class=\"material-tip\">需要注意：药物机理决定了不同药物的不良反应及与其它药物间的相互作用。\u003C/p>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light4\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 正确的用药方法：用法用量与服药时间\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">⏰\u003C/span>\n      用药方案由专科医生结合体重、既往用药和不良反应决定。这里总结常见用法差异和注意点：\n    \u003C/p>\n    \u003Cul class=\"material-ul\">\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">注射类（曲妥珠单抗、帕妥珠单抗、T-DM1）：\u003C/span> \n        需要在医院，由护士静脉滴注。首次通常负荷量较大，随后定期维持，一般每21天一次。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">口服类（拉帕替尼、吡咯替尼）：\u003C/span> \n        建议每日一次或每日两次，具体剂量遵医嘱。拉帕替尼通常需空腹服用（餐前至少1小时或餐后至少1小时），吡咯替尼则建议餐后服用，以利药物吸收。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-tip\">特别提醒：随意更改用药时间或剂量，可能降低疗效或加大毒副作用。用药时保证饮水充足，吞服整片，避免咀嚼或掰碎。\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light5\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 药物相互作用：哪些药绝对不能同用？\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">⚠️\u003C/span>\n      靶向药可能和其他很多药有相互作用，包括：\n    \u003C/p>\n    \u003Cul class=\"material-ul\">\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">拉帕替尼：\u003C/span> \n        避免与酮康唑、伊曲康唑等强CYP3A4抑制剂同用；同时服用地塞米松、利福平等诱导剂可加速其代谢，疗效降低。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">吡咯替尼：\u003C/span> \n        与抗酸药或质子泵抑制剂合用可能影响吸收，应错开2小时左右。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">注射类单抗药物：\u003C/span> \n        对药物代谢系统影响有限，但与其他细胞毒类药需要医生严密监控。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">T-DM1：\u003C/span>\n        不建议与某些抗真菌药（如伏立康唑）或强酶抑制药共同使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-tip\">正确做法：用药前主动向医生说明所有正在服用的药物，包括保健品、维生素。换药时务必通报用药史。\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light2\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 特殊人群与剂量调整\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">👤\u003C/span>\n      特殊人群对HER2靶向药需求各有不同：\n    \u003C/p>\n    \u003Cul class=\"material-ul\">\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">老年患者：\u003C/span> 部分代谢能力下降，起始剂量与监测更需谨慎，避免肝肾损害。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">肾功能不全：\u003C/span> 拉帕替尼、吡咯替尼多经肝脏代谢，轻中度肾损伤时通常不用调整剂量，但严重肾功能异常需医生评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">肝功能损害：\u003C/span> 小分子口服药对肝功能要求高，中重度肝损害患者需特别调整或避免使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"material-strong\">孕妇和哺乳期：\u003C/span> 目前多数HER2靶向药妊娠禁用，哺乳期应停止哺乳。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"material-tip\">正确做法：用药前告知医生自身肝肾状态和生育计划。\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light3\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 常见不良反应及处理方法\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">🩺\u003C/span>\n      不同药物常见副作用各有侧重。\u003Cbr>\n      \u003Cspan class=\"material-strong\">曲妥珠单抗/帕妥珠单抗：\u003C/span> 可能出现输液相关反应（如寒战、发热）、心脏毒性（心衰风险微增），部分人有轻度腹泻。\u003Cbr>\n      \u003Cspan class=\"material-strong\">拉帕替尼/吡咯替尼：\u003C/span> 腹泻、皮疹、恶心、食欲下降较多见。吡咯替尼相关腹泻发生率可达80%以上，严重者需控药。\u003Cbr>\n      \u003Cspan class=\"material-strong\">T-DM1：\u003C/span> 可能有血小板减少、肝酶升高等。\u003Cbr>\n      \u003Cspan class=\"material-strong\">如何应对：\u003C/span>\n      \u003C/p>\u003Cul class=\"material-ul\">\n        \u003Cli>出现腹泻：应及时补液，必要时使用止泻药，重度症状及时就医。\u003C/li>\n        \u003Cli>输注不适：减慢滴速或暂停，严重者通知护士立即处理。\u003C/li>\n        \u003Cli>皮疹、乏力：多为可逆反应，注意皮肤护理，与医生沟通调整用药。\u003C/li>\n      \u003C/ul>\n      数据显示，拉帕替尼类药物中度以上腹泻发生率为27%，正确应对可显著降低危害。\u003Cspan class=\"material-ref\">(Geyer CE et al., 2006)\u003C/span>\n    \u003Cp>\u003C/p>\n    \u003Cdiv class=\"material-case\">\n      \u003Cspan class=\"material-case-title\">用药案例：\u003C/span>\n      \u003Cspan class=\"material-case-text\">临床上有患者在吡咯替尼治疗期间出现严重腹泻，经及时调整剂量和对症治疗后改善。\u003C/span>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light4\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 耐药性应对及用药方案更换技巧\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      \u003Cspan class=\"material-emoji\">🌀\u003C/span>\n      靶向治疗中出现耐药情况并不少见。出现疗效减弱时，应及时与医生沟通，避免自行停药或换药。\n      \u003Cbr>\n      \u003Cspan class=\"material-strong\">常见药物更换逻辑：\u003C/span>\n      \u003C/p>\u003Cul class=\"material-ul\">\n        \u003Cli>曲妥珠单抗耐药时，考虑更换为T-DM1或联合使用帕妥珠单抗。\u003C/li>\n        \u003Cli>小分子药物耐药时，建议切换至其他类别或联合化疗。\u003C/li>\n        \u003Cli>多次更换药物无效时，需重新评估HER2状态。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-case\">\n        \u003Cspan class=\"material-case-title\">用药案例：\u003C/span>\n        \u003Cspan class=\"material-case-text\">有位患者曲妥珠单抗治疗一年后出现耐药，医生更换为双靶向联合方案后获得持续用药收益。\u003C/span>\n      \u003C/div>\n      \u003Cp class=\"material-tip\">正确做法：耐药后绝不能擅自加大剂量或随意切换药物，务必在医生指导下调整方案并定期复查。\u003C/p>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light2\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 药品保存、有效期与处理细节\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      各类靶向药物保存要求不同。\u003Cbr>\n      \u003Cspan class=\"material-strong\">曲妥珠单抗、帕妥珠单抗、T-DM1：\u003C/span> 未开封需置于2-8℃冷藏，避免冷冻和阳光直射。开启后一般要求24小时内用完，剩余药物勿再次使用。\u003Cbr>\n      \u003Cspan class=\"material-strong\">拉帕替尼、吡咯替尼：\u003C/span> 常温下避光存放（一般不超过25℃），保持干燥，不要将不同药片混装。\u003Cbr>\n      \u003Cspan class=\"material-strong\">过期药品：\u003C/span> 切勿自行处理或丢弃。可送至专业药品回收点，或交由药师安排处理。\n      \u003C/p>\u003Cp class=\"material-tip\">正确做法：避免儿童接触药品，药瓶标签标记开封时间，过期药立即丢弃，切勿继续服用。\u003C/p>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light3\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 漏服与过量用药处理方法\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      用药不时有疏忽。遇到漏服或者用量超标时的应急措施有区别：\n      \u003C/p>\u003Cul class=\"material-ul\">\n        \u003Cli>\n          \u003Cspan class=\"material-strong\">口服药漏服：\u003C/span> 如果距离下次服药时间较远，可尽快补服；如已临近下次服药，应跳过不补，严禁一次服用双倍剂量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-strong\">注射药漏用：\u003C/span> 应及时联系医疗机构，由专业人员根据上次用药时间调整。\n        \u003C/li>\n        \u003Cli>\n          \u003Cspan class=\"material-strong\">过量服用：\u003C/span> 出现不适如恶心、头晕、腹泻等应立即就医，同时告知医生所用药品及剂量。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"material-case\">\n        \u003Cspan class=\"material-case-title\">用药案例：\u003C/span>\n        \u003Cspan class=\"material-case-text\">有患者误服多片拉帕替尼，出现恶心，及时到医院洗胃并接受观察，未遗留后遗症。\u003C/span>\n      \u003C/div>\n      \u003Cp class=\"material-tip\">正确做法：出现漏服或误服后，第一时间寻求专业指导，不要自行处理或调整剂量。\u003C/p>\n    \u003Cp>\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light4\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 总结与用药安全回顾\u003C/h2>\n    \u003C/div>\n    \u003Cp class=\"material-text\">\n      HER2靶向药物正在不断丰富乳腺癌的治疗手段，提升了药物可及性和便捷性。不过，用药过程中剂型区别、服药时间、药物相互作用、不良反应处理等，每一步都关乎疗效。\u003Cspan class=\"material-emoji\">💡\u003C/span>\n      \u003Cbr>\n      最需要注意的，一是“不擅自调整用量”，二是“用药前主动说明所有药物”。真正做到合理用药，才能把药效优势发挥到最大，尽量减少风险。若遇用药难题，请及时咨询医生或专业药师，提升用药安全感受，守护身体健康。\n    \u003C/p>\n    \u003Cp class=\"material-strong material-bottomcall\">最后，记得：用药无小事，细节才是关键！\u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\">\n    \u003Cdiv class=\"material-section-bg material-bg-light5\">\n      \u003Ch2 class=\"material-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">文献与参考资料（References）\u003C/h2>\n    \u003C/div>\n    \u003Cul class=\"material-ref-ul\">\n      \u003Cli>\n        Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., & Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. \n        \u003Cem>New England Journal of Medicine, 355\u003C/em>(26), 2733-2743.\n      \u003C/li>\n      \u003Cli>\n        Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., & Cortés, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA study). \n        \u003Cem>New England Journal of Medicine, 372\u003C/em>(8), 724-734.\n      \u003C/li>\n      \u003Cli>\n        Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., & Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. \n        \u003Cem>New England Journal of Medicine, 367\u003C/em>(19), 1783-1791.\n      \u003C/li>\n      \u003Cli>\n        Xu, B., Yan, M., Ma, F., Hu, X., Feng, J., Ouyang, Q., & Xie, Y. (2021). Pyrotinib as second‐line therapy for HER2‐positive metastatic breast cancer: A randomized, controlled trial. \n        \u003Cem>Journal of Clinical Oncology, 39\u003C/em>(3), 224-234.\n      \u003C/li>\n      \u003Cli>\n        Programme, W. H. O. (2022). WHO Model List of Essential Medicines – 22nd List,\n        \u003Cem>World Health Organization\u003C/em>.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.material-content {\n  font-family: 'Segoe UI', Arial, 'Microsoft YaHei', sans-serif;\n  color: #26313d;\n  background: #f5f7fa;\n  padding: 32px 8% 40px 8%;\n  font-size: 18px;\n  line-height: 1.8;\n  max-width: 920px;\n  margin:auto;\n  box-shadow:0 1px 8px 1px #dbe2ef33;\n}\n.material-title {\n  font-size: 2.3em;\n  color:#314781;\n  font-weight: bold;\n  line-height:1.3;\n  margin-bottom: 20px;\n  background: linear-gradient(90deg,#bccaf1 40%, #fff 100%);\n  padding:32px 0 28px 32px;\n  border-radius: 18px 30px 0 0;\n  letter-spacing: 1px;\n  box-shadow: 0 1px 6px 1px #f7fafc77;\n}\n.material-section {\n  margin-bottom:36px;\n}\n.material-section-bg {\n  padding: 16px 0 10px 20px;\n  border-radius: 16px 30px 6px 8px;\n  margin-bottom:14px;\n  min-height:40px;\n}\n.material-section-title {\n  font-size:1.3em;\n  letter-spacing: 0.5px;\n  color: #314781;\n  font-weight: 700;\n  display:inline-block;\n  vertical-align:middle;\n}\n.material-bg-light {\n  background: linear-gradient(90deg,#e9f0fb 60%,#fff 115%);\n}\n.material-bg-light2 {\n  background: linear-gradient(90deg,#f1f3e9 55%,#fff 105%);\n}\n.material-bg-light3 {\n  background: linear-gradient(90deg,#f1edfa 60%,#fff 115%);\n}\n.material-bg-light4 {\n  background: linear-gradient(90deg,#fdf6ed 66%,#fff 120%);\n}\n.material-bg-light5 {\n  background: linear-gradient(90deg,#e3f1ee 70%,#fff 105%);\n}\n.material-text {\n  margin-left:12px;\n  margin-bottom:0.8em;\n  color:#26313d;\n}\n.material-ul {\n  margin-left: 28px;\n  margin-top:-5px;\n  margin-bottom:12px;\n  padding-left: 0;\n  list-style: disc;\n}\n.material-ul li {\n  margin-bottom:8px;\n  line-height:1.74;\n}\n.material-tip {\n  background: #f6ffe2;\n  color: #547600;\n  border-left: 6px solid #bbd87b;\n  border-radius: 6px 22px 10px 6px;\n  margin: 16px 0 8px 0;\n  padding: 10px 22px 10px 16px;\n  font-size: 1.04em;\n  font-weight:450;\n  letter-spacing:0.2px;\n  box-shadow: 0 0.5px 2.5px #dbe2ef18;\n}\n.material-case {\n  background: #f5f0ff;\n  border-left: 6px solid #b9a9f8;\n  border-radius: 7px 23px 12px 5px;\n  margin: 16px 0 10px 0;\n  padding: 11px 24px 8px 14px;\n  font-size: 1.05em;\n  color: #61358e;\n}\n.material-case-title {\n  color: #4d3462;\n  font-weight:600;\n}\n.material-case-text {\n  color: #543b6e;\n}\n.material-ref {\n  font-size:0.95em;\n  color:#7e8998;\n  margin-left: 7px;\n}\n.material-ref-ul {\n  margin-left: 40px;\n  color: #474f63;\n  font-size:1.05em;\n  margin-bottom:8px;\n}\n.material-emoji {\n  font-size:1.13em;\n  vertical-align: middle;\n}\n.material-strong {\n  font-weight:600;\n  color:#2c387e;\n}\n.material-bottomcall {\n    font-size:1.23em;\n    color:#709344;\n    font-weight:600;\n    margin-left:4px;\n    margin-top:10px;\n}\n@media (max-width: 650px){\n  .material-content {padding:10px 4% 20px 4%;}\n  .material-title {font-size: 1.4em;padding:18px 0 15px 16px;}\n  .material-section-bg {padding: 10px 0 6px 10px;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"material-content\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44",550,"2025-08-29 10:44:59","乳腺癌, HER2靶向药物, 药物耐药性, 治疗指南, 药物相互作用","本文详细介绍乳腺癌靶向药物的分类、用法、耐药性应对等实用技巧，帮助患者更好管理HER2阳性乳腺癌，提高用药安全性与治疗效果。","2025-09-08 13:46:14",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]